Portfolio

Pursues discovery and development of novel pharmaceutical, cosmetic and medical device products that are applied to the skin. The company is at development stage and remains private.

Develops and delivers customized life sciences education and informational programs for corporate, institutional and academic clients). The company at fledgling stage and remains private.

An innovator of topical drug and beauty care products using proprietary high throughput experimentation technologies). Acquired by Nuvo Research Inc. in December 2005.

A high throughput experimentation catalyst and materials discovery company. Acquired by BASF in June 2008.

An integrated voice messaging technology and services company. Acquired by Godaddy, Inc. in May 2016.

DMK Pharmaceuticals is developing a novel second-generation mixed opioid receptor agonist for treatment of moderate-to-sever pain. 47 times more potent than morphine, DPI-125 has a much better safety profile and dramatically-reduced risk of dependency and misuse. DMK is developing DPI-125 in transdermal, buccal and oral administration formats.